drugset / Trial / NCT00886808

Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema

NCT00886808

Phase 1 Completed 15 enrolled iCo Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.

Timeline

Start
2008-02
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject iCo-007 Unknown 110 ug Intravitreal
Subject iCo-007 Unknown 350 ug Intravitreal
Subject iCo-007 Unknown 700 ug Intravitreal
Subject iCo-007 Unknown 1000 ug Intravitreal